$LBRX News

LB Pharmaceuticals (LBRX) Stock Fair Value Rises As LB 102 Outlook Shifts

LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP Congress

LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Canaccord Genuity Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $65

LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment

Guggenheim Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $80

Roth Capital Downgrades LB Pharmaceuticals to Neutral, Lowers Price Target to $35

Needham Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $68

LB Pharmaceuticals Files Prospectus For Offering Mixed Shelf; Terms Undisclosed

LB Pharmaceuticals: One Methyl Group, Two Enantiomers, And A Bullish $5 Billion Opportunity

LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical Officer

2 Reasons LB Pharmaceuticals (LBRX) Looks Pricey Following Its CFO Appointment

LB Pharmaceuticals to Participate in Upcoming September Investor Events

LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer

LB Pharmaceuticals Appoints Joseph Miller CFO

HC Wainwright & Co. Maintains Buy on LB Pharmaceuticals, Raises Price Target to $60

BMO Capital Maintains Outperform on LB Pharmaceuticals, Raises Price Target to $54

LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

LB Pharmaceuticals Q2 EPS $(1.71) Misses $(0.80) Estimate

HC Wainwright & Co. Reiterates Buy on LB Pharmaceuticals, Maintains $45 Price Target